:root{–bg:#020817;–nv:#040d1b;–card:#080f1c;–blue:#1e56d9;–cyan:#00c8ff;–green:#10b981;–amber:#f59e0b;–purple:#a855f7;–muted:#4a6a8a;–text:#e0eaff;–line:rgba(255,255,255,.07)}
.pl{font-family:Inter,system-ui,sans-serif;background:var(–bg);color:var(–text);min-height:100vh}
.pl *,.pl *::before,.pl *::after{box-sizing:border-box;margin:0;padding:0}
.pl a{text-decoration:none;color:inherit}
.sh{width:min(1180px,calc(100% – 28px));margin:0 auto}
.pl-hero{background:radial-gradient(ellipse at 65% 35%,rgba(30,86,217,.25),transparent 52%),radial-gradient(ellipse at 12% 8%,rgba(168,85,247,.15),transparent 40%),#030c1c;padding:clamp(44px,6vw,80px) 0 36px;border-bottom:1px solid rgba(30,86,217,.18);position:relative;overflow:hidden}
.pl-hero::before{content:””;position:absolute;inset:0;background-image:linear-gradient(rgba(148,163,184,.025) 1px,transparent 1px),linear-gradient(90deg,rgba(148,163,184,.025) 1px,transparent 1px);background-size:52px 52px;pointer-events:none}
.pl-kicker{font-size:10px;font-weight:900;letter-spacing:.2em;text-transform:uppercase;color:var(–cyan);margin-bottom:12px}
.pl-h1{font-size:clamp(24px,4vw,52px);font-weight:950;color:#fff;line-height:.93;margin-bottom:14px}
.pl-h1 span{color:var(–cyan)}
.pl-hsub{color:#7a9ab8;font-size:15px;line-height:1.7;max-width:680px;margin-bottom:22px}
.pl-hero-meta{display:flex;flex-wrap:wrap;gap:14px}
.pl-meta-i{font-size:11px;font-weight:800;color:#2d4560;display:flex;align-items:center;gap:5px}
.pl-meta-i::before{content:”•”;color:var(–cyan)}
.pl-main{padding:40px 0 80px}
.pl-grid{display:grid;grid-template-columns:1fr 260px;gap:28px;align-items:start}
@media(max-width:900px){.pl-grid{grid-template-columns:1fr}}
.pl-article h2{font-size:clamp(18px,2.5vw,26px);font-weight:950;color:#fff;text-transform:uppercase;margin:32px 0 12px;padding-top:8px;border-top:1px solid rgba(255,255,255,.06)}
.pl-article h2:first-child{margin-top:0;border-top:none;padding-top:0}
.pl-article h3{font-size:15px;font-weight:900;color:var(–cyan);margin:22px 0 8px}
.pl-article p{color:#4a6a8a;font-size:13px;line-height:1.85;margin-bottom:12px}
.pl-article a{color:var(–cyan);font-weight:700}
.pl-article ul,.pl-article ol{padding-left:18px;margin:8px 0 14px;display:flex;flex-direction:column;gap:6px}
.pl-article li{color:#4a6a8a;font-size:13px;line-height:1.65}
.pl-article strong{color:#94a3b8}
.pl-table-wrap{overflow-x:auto;margin:18px 0}
.pl-table{width:100%;border-collapse:collapse;font-size:12px}
.pl-table th{background:rgba(30,86,217,.15);color:#93c5fd;font-size:10px;font-weight:900;letter-spacing:.08em;text-transform:uppercase;padding:10px 14px;text-align:left;border-bottom:1px solid rgba(30,86,217,.3)}
.pl-table td{padding:10px 14px;border-bottom:1px solid rgba(255,255,255,.05);color:#4a6a8a;vertical-align:top}
.pl-table tr:last-child td{border-bottom:none}
.pl-table td:first-child{color:#94a3b8;font-weight:800}
.pl-table .win{color:var(–green);font-weight:900}
.pl-verdict-g{display:grid;grid-template-columns:1fr 1fr;gap:14px;margin:18px 0}
@media(max-width:600px){.pl-verdict-g{grid-template-columns:1fr}}
.pl-verdict{background:var(–card);border:1px solid var(–line);border-radius:8px;padding:18px}
.pl-verdict-name{font-size:12px;font-weight:950;text-transform:uppercase;letter-spacing:.08em;margin-bottom:10px;padding-bottom:8px;border-bottom:1px solid rgba(255,255,255,.07)}
.pl-verdict-item{display:flex;align-items:flex-start;gap:7px;font-size:11px;color:#4a6a8a;margin-bottom:5px;line-height:1.5}
.pl-verdict-item::before{content:”✓”;color:var(–green);font-weight:900;font-size:10px;margin-top:1px;flex-shrink:0}
.pl-stats{display:grid;grid-template-columns:repeat(4,1fr);gap:12px;margin:18px 0;background:rgba(8,15,28,.5);border:1px solid var(–line);border-radius:8px;padding:20px}
@media(max-width:700px){.pl-stats{grid-template-columns:repeat(2,1fr)}}
.pl-stat-item{text-align:center}
.pl-stat-item strong{display:block;font-size:22px;font-weight:950;color:var(–cyan)}
.pl-stat-item span{font-size:10px;color:#2d4560;font-weight:700;text-transform:uppercase;letter-spacing:.06em;margin-top:3px;display:block}
.pl-callout{background:rgba(30,86,217,.08);border-left:3px solid var(–blue);border-radius:0 7px 7px 0;padding:14px 18px;margin:18px 0}
.pl-callout p{color:#4a6a8a;font-size:12px;line-height:1.75;margin:0}
.pl-callout strong{color:#93c5fd}
.pl-products-g{display:grid;grid-template-columns:repeat(auto-fill,minmax(190px,1fr));gap:12px;margin:20px 0}
.pl-pcard{background:var(–card);border:1px solid var(–line);border-radius:8px;overflow:hidden;transition:border-color .18s}
.pl-pcard:hover{border-color:rgba(30,86,217,.4)}
.pl-pcard-img{height:130px;overflow:hidden;background:linear-gradient(160deg,#0c1a2e,#060e1c)}
.pl-pcard-img img{width:100%;height:100%;object-fit:cover;display:block}
.pl-pcard-body{padding:10px 12px}
.pl-pcard-name{font-size:12px;font-weight:900;color:#e0eaff;margin-bottom:3px}
.pl-pcard-price{font-size:14px;font-weight:950;color:#fff;margin-bottom:8px}
.pl-pcard-atc{display:flex;align-items:center;justify-content:center;height:28px;background:var(–blue);border-radius:5px;color:#fff!important;font-size:10px;font-weight:900}
.pl-sidebar{display:flex;flex-direction:column;gap:14px;position:sticky;top:8px}
@media(max-width:900px){.pl-sidebar{display:none}}
.pl-scard{background:var(–card);border:1px solid var(–line);border-radius:8px;padding:16px}
.pl-scard-title{font-size:10px;font-weight:900;letter-spacing:.12em;text-transform:uppercase;color:var(–cyan);margin-bottom:10px}
.pl-slink{display:flex;align-items:center;justify-content:space-between;padding:6px 0;border-bottom:1px solid rgba(255,255,255,.04);color:var(–muted);font-size:11px;font-weight:700;transition:color .12s}
.pl-slink:last-of-type{border-bottom:none}
.pl-slink:hover{color:#e0eaff}
.pl-slink::after{content:”›”;color:#1e3a5f;font-size:13px}
.pl-cta{background:linear-gradient(135deg,rgba(30,86,217,.12),rgba(0,200,255,.06));border:1px solid rgba(0,200,255,.18);border-radius:8px;padding:16px}
.pl-cta h4{font-size:12px;font-weight:950;color:var(–cyan);text-transform:uppercase;margin-bottom:6px}
.pl-cta p{font-size:11px;color:var(–muted);line-height:1.55;margin-bottom:10px}
.pl-cta-btn{display:flex;align-items:center;justify-content:center;height:30px;background:var(–blue);border-radius:5px;color:#fff!important;font-size:10px;font-weight:900;width:100%;margin-bottom:7px}
.pl-ruo{background:rgba(30,86,217,.07);border:1px solid rgba(30,86,217,.15);border-radius:6px;padding:11px 15px;margin-top:24px}
.pl-ruo p{color:#2d4560;font-size:11px;line-height:1.65;margin:0}
Metabolic Research | Comparison Hub
Metabolic Peptide Comparison Hub — GLP-1, Dual & Triple Agonist Index
The complete research index for comparing metabolic peptides across the GLP-1 agonist class — single, dual, and triple receptor agonists. Mechanism summaries, receptor targets, clinical data references, and links to detailed compound comparisons.
Metabolic ResearchGLP-1 Class IndexAll Receptor Agonists
Metabolic Research Peptide Index
This hub indexes all major metabolic research peptides in the GLP-1 receptor agonist class, organized by receptor activation profile. Use this page to navigate compound comparisons, understand mechanistic differences between generations, and identify the right compound for your research objective.
3Agonist Generations
7+Metabolic Compounds
3Receptor Systems
COAEvery Batch
Generation Comparison: Single → Dual → Triple
| Generation | Compound | GLP-1R | GIPR | GCGR | Amylin | Peak Weight Loss |
|---|
| 1st — Mono | Semaglutide | ✓ | ✗ | ✗ | ✗ | ~15% |
| 2nd — Dual | Tirzepatide | ✓ | ✓ | ✗ | ✗ | ~22% |
| 3rd — Triple | Retatrutide | ✓ | ✓ | ✓ | ✗ | ~28.7% |
| Amylin combo | Cagrilintide | ✗ | ✗ | ✗ | ✓ | Combo with sema |
| hGH fragment | AOD-9604 | ✗ | ✗ | ✗ | ✗ | β3-AR lipolysis |
Compound-by-Compound Comparison Pages
Key Research Questions Answered
What additional metabolic effect does dual agonism provide over single GLP-1R agonism?
Adding GIPR activation (tirzepatide vs semaglutide) contributes adipose tissue GIPR signaling, amplified insulin secretion, and apparent GLP-1R nausea attenuation. In clinical comparison studies, tirzepatide consistently shows approximately 6–7 percentage points greater weight reduction than semaglutide, attributed primarily to the GIPR contribution.
What does glucagon receptor activation add in triple agonists?
GCGR activation (retatrutide vs tirzepatide) adds thermogenic energy expenditure via brown adipose tissue, enhanced hepatic lipid oxidation, and direct adipocyte lipolysis — effects neither GLP-1R nor GIPR agonism provides. The insulinotropic counterbalancing effect of GLP-1R/GIPR co-activation maintains glycemic stability while GCGR’s thermogenic effects are retained. Published network meta-analysis data shows retatrutide outperforms tirzepatide by approximately −4.5 kg absolute weight reduction.
When should I use AOD-9604 vs GLP-1 class compounds?
AOD-9604 (hGH fragment 177–191) operates through an entirely different mechanism — β3-adrenergic receptor activation and adipocyte lipolysis — independent of the incretin system. It is used in research focused on hGH C-terminal fragment pharmacology and non-incretin lipolysis pathways rather than GLP-1R agonism.
All Metabolic Research Peptides
Research Use Only: All compounds referenced are strictly for laboratory and in vitro research purposes only. Not for human use, veterinary use, or diagnostic/treatment purposes. OligoPoly Labs sells research-grade peptides exclusively to qualified researchers.
Research Compounds Referenced in This Guide
For Research Use Only · Third-Party Tested · COA Verified · Ships from Houston TX
